Prosecution Insights
Last updated: August 16, 2026

Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
1
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (75%)
1
Medium (25%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
Multi-statute (no §101)3 (75%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MCCORMICK, CATHERINE LYNN 1 48.8% +35.6%
PARISI, JESSICA DANIELLE 1 77.1% +32.4%
ZHU, JIANJIAN 1 61.0% +83.7%
VIVLEMORE, TRACY ANN 1 73.0% +6.7%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18249511 METHOD FOR NUCLEIC ACID DETECTION BY OLIGO HYBRIDIZATION AND PCR-BASED AMPLIFICATION PARISI, JESSICA DANIELLE 18d overdue
18015489 METHOD FOR GENERATING A THREE-DIMENSIONAL NEUROMUSCULAR ORGANOID IN VITRO ZHU, JIANJIAN 11d overdue
17593741 ENHANCEMENT OF CYTOLYTIC T-CELL ACTIVITY BY INHIBITING EBAG9 VIVLEMORE, TRACY ANN

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18249511 METHOD FOR NUCLEIC ACID DETECTION BY OLIGO HYBRIDIZATION AND PCR-BASED AMPLIFICATION PARISI, JESSICA DANIELLE 18d overdue
18015489 METHOD FOR GENERATING A THREE-DIMENSIONAL NEUROMUSCULAR ORGANOID IN VITRO ZHU, JIANJIAN 11d overdue
18335765 SELF-ORGANIZING NEURO-MUSCULAR JUNCTION CELL CULTURE MODEL MCCORMICK, CATHERINE LYNN

Top Art Units

Art UnitApps
1638 2
1684 1
1631 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18335765 SELF-ORGANIZING NEURO-MUSCULAR JUNCTION CELL CULTURE MODEL MCCORMICK, CATHERINE LYNN 1638 §103 Non-Final OA Pending Jun 15, 2023
18249511 METHOD FOR NUCLEIC ACID DETECTION BY OLIGO HYBRIDIZATION AND PCR-BASED AMPLIFICATION PARISI, JESSICA DANIELLE 1684 §102§112 Final Rejection 18d overdue Pending Apr 18, 2023
18015489 METHOD FOR GENERATING A THREE-DIMENSIONAL NEUROMUSCULAR ORGANOID IN VITRO ZHU, JIANJIAN 1631 §103§112Other Final Rejection 11d overdue Pending Jan 10, 2023
17593741 ENHANCEMENT OF CYTOLYTIC T-CELL ACTIVITY BY INHIBITING EBAG9 VIVLEMORE, TRACY ANN 1638 §103§112 Final Rejection Pending Sep 23, 2021

Managing Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month